Pierrepont Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2026-09-22.
Pierrepont Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on September 22, 2026. The filing reports $2.41M sold. Its industry group is Pharmaceuticals. It names Peter Barber (Executive Officer, Director), Daniel DiPietro (Director), Matthew Wyckoff (Director) (SEC Form D/A, September 22, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Pierrepont Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-22 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Pierrepont Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Pierrepont Therapeutics, Inc., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Pierrepont Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Pierrepont Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Pierrepont Therapeutics, Inc. →Get the full cited report on Pierrepont Therapeutics, Inc.
What the filing shows about Pierrepont Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pierrepont Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Pierrepont Therapeutics, Inc.'s address as Downstate Technology Center, Suite 327A, 760 Parkside Avenue, Brooklyn, NY 11203.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Pierrepont Therapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Pierrepont Therapeutics, Inc. See pricing
Pierrepont Therapeutics, Inc. is a registered filer with the SEC (CIK 2019360) and has filed since 2024-04-15. 1 filing is on record, the latest on 2024-04-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Pierrepont Therapeutics, Inc.'s Form D of 2026-09-22 names Peter Barber, Daniel DiPietro and Matthew Wyckoff as its officers, directors or promoters.
Its new offerings report $2.11M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $2.41M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Other than the payment of salaries and other compensation and benefits and reimbursement of expenses, no officer, director, partner, manager or promoter will receive any payments from the proceeds of this offering.
Peter Barber is named as Executive Officer and Director on the Form D that Pierrepont Therapeutics, Inc. filed with the SEC on 22 September 2026, one of 3 people that filing names.
Daniel DiPietro is named as Director on the Form D that Pierrepont Therapeutics, Inc. filed with the SEC on 22 September 2026, one of 3 people that filing names.
Matthew Wyckoff is named as Director on the Form D that Pierrepont Therapeutics, Inc. filed with the SEC on 22 September 2026, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2026-09-22 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Pierrepont Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pierrepont Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pierrepont Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Pierrepont Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Pierrepont Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Pierrepont Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/pierrepont-therapeutics-inc-form-d-000003